{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Schedule+B&page=2", "query": { "intervention": "Schedule B", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Schedule+B&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-18T07:45:17.277Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03636906", "title": "Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Respiratory Syncytial Virus Infections" ], "interventions": [ { "name": "RSV (GSK3389245A) lower dose formulation vaccine", "type": "BIOLOGICAL" }, { "name": "RSV (GSK3389245A) higher dose formulation vaccine", "type": "BIOLOGICAL" }, { "name": "GSK's multicomponent meningococcal B vaccine", "type": "BIOLOGICAL" }, { "name": "Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine", "type": "BIOLOGICAL" }, { "name": "GSK's pneumococcal polysaccharide conjugate vaccine", "type": "BIOLOGICAL" }, { "name": "GSK's meningococcal group A, C, W-135 and Y conjugate vaccine", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "6 Months", "maximum_age": "7 Months", "sex": "ALL", "summary": "6 Months to 7 Months" }, "enrollment_count": 201, "start_date": "2019-04-08", "completion_date": "2021-07-22", "has_results": true, "last_update_posted_date": "2022-07-27", "last_synced_at": "2026-09-18T07:45:17.277Z", "location_count": 4, "location_summary": "Atlanta, Georgia • Nampa, Idaho • Louisville, Kentucky + 1 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Nampa", "state": "Idaho" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03636906" }, { "nct_id": "NCT02214433", "title": "A Multiple Dose Study of Debio 1450 [Intravenous (IV) and Oral] in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bacterial Infections" ], "interventions": [ { "name": "Placebo IV Solution", "type": "DRUG" }, { "name": "Debio 1450 IV Solution", "type": "DRUG" }, { "name": "Placebo Tablet or Capsule", "type": "DRUG" }, { "name": "Debio 1450 Tablet", "type": "DRUG" }, { "name": "Debio 1450 Capsule", "type": "DRUG" }, { "name": "Debio 1450 Oral Solution", "type": "DRUG" }, { "name": "Pantoprazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Debiopharm International SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 70, "start_date": "2014-08", "completion_date": "2015-02", "has_results": false, "last_update_posted_date": "2015-02-25", "last_synced_at": "2026-09-18T07:45:17.277Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02214433" }, { "nct_id": "NCT03814590", "title": "A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Respiratory Syncytial Virus Infections" ], "interventions": [ { "name": "RSV Vaccine (GSK3844766A) unadjuvanted low dose", "type": "BIOLOGICAL" }, { "name": "RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01E", "type": "BIOLOGICAL" }, { "name": "RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01B", "type": "BIOLOGICAL" }, { "name": "RSV Vaccine (GSK3844766A) unadjuvanted medium dose", "type": "BIOLOGICAL" }, { "name": "RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01E", "type": "BIOLOGICAL" }, { "name": "RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01B", "type": "BIOLOGICAL" }, { "name": "RSV Vaccine (GSK3844766A) unadjuvanted high dose", "type": "BIOLOGICAL" }, { "name": "RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01E", "type": "BIOLOGICAL" }, { "name": "RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01B", "type": "BIOLOGICAL" }, { "name": "Placebo (Saline solution)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 1053, "start_date": "2019-01-21", "completion_date": "2020-11-30", "has_results": true, "last_update_posted_date": "2022-08-05", "last_synced_at": "2026-09-18T07:45:17.277Z", "location_count": 18, "location_summary": "Jacksonville, Florida • Miami, Florida • Stockbridge, Georgia + 15 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Stockbridge", "state": "Georgia" }, { "city": "Lenexa", "state": "Kansas" }, { "city": "Wichita", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03814590" }, { "nct_id": "NCT04951778", "title": "Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia, Myeloid, Acute", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "CC-91633", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2021-12-02", "completion_date": "2025-07-30", "has_results": false, "last_update_posted_date": "2025-08-27", "last_synced_at": "2026-09-18T07:45:17.277Z", "location_count": 5, "location_summary": "Boston, Massachusetts • St Louis, Missouri • Houston, Texas + 1 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Houston", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04951778" }, { "nct_id": "NCT04885530", "title": "ACTIV-6: COVID-19 Study of Repurposed Medications", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Covid19" ], "interventions": [ { "name": "Ivermectin", "type": "DRUG" }, { "name": "Fluvoxamine", "type": "DRUG" }, { "name": "Fluticasone", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Montelukast", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Susanna Naggie, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": null, "sex": "ALL", "summary": "30 Years and older" }, "enrollment_count": 10956, "start_date": "2021-06-08", "completion_date": "2024-04-29", "has_results": true, "last_update_posted_date": "2025-11-17", "last_synced_at": "2026-09-18T07:45:17.277Z", "location_count": 110, "location_summary": "Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 96 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04885530" }, { "nct_id": "NCT00609999", "title": "Ph I Dasatinib + Erlotinib in Recurrent MG", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma", "Gliosarcoma" ], "interventions": [ { "name": "Erlotinib and Dasatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2008-01", "completion_date": "2010-07", "has_results": false, "last_update_posted_date": "2014-07-16", "last_synced_at": "2026-09-18T07:45:17.277Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00609999" }, { "nct_id": "NCT07625644", "title": "BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Small Cell Lung Cancer Extensive Stage", "Small-cell Lung Cancer", "Small Cell Carcinoma", "Sclc", "SCLC,Extensive Stage", "Lung Cancer", "Lung Cancer Metastatic", "Lung Cancer Stage IV" ], "interventions": [ { "name": "BL-M14D1 and Atezolizumab", "type": "DRUG" }, { "name": "Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SystImmune Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 550, "start_date": "2026-08-04", "completion_date": "2031-06", "has_results": false, "last_update_posted_date": "2026-09-17", "last_synced_at": "2026-09-18T07:45:17.277Z", "location_count": 7, "location_summary": "Springdale, Arkansas • Glendale, California • Long Beach, California + 4 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "Glendale", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07625644" }, { "nct_id": "NCT00246571", "title": "Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "SU011248", "type": "DRUG" }, { "name": "Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 217, "start_date": "2006-01", "completion_date": "2011-06", "has_results": true, "last_update_posted_date": "2012-07-12", "last_synced_at": "2026-09-18T07:45:17.277Z", "location_count": 77, "location_summary": "Corona, California • Fullerton, California • Glendora, California + 59 more", "locations": [ { "city": "Corona", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Glendora", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00246571" }, { "nct_id": "NCT06692764", "title": "A Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atherosclerotic Cardiovascular Disease" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "AZD0780", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 202, "start_date": "2024-10-30", "completion_date": "2025-05-02", "has_results": false, "last_update_posted_date": "2026-02-18", "last_synced_at": "2026-09-18T07:45:17.277Z", "location_count": 26, "location_summary": "Inglewood, California • Northridge, California • Pomona, California + 20 more", "locations": [ { "city": "Inglewood", "state": "California" }, { "city": "Northridge", "state": "California" }, { "city": "Pomona", "state": "California" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Hialeah", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06692764" }, { "nct_id": "NCT02793544", "title": "HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelodysplastic Syndrome (MDS)", "Chronic Lymphocytic Leukemia (CLL)", "Chemotherapy-sensitive Lymphoma", "Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma", "Acute Myelogenous Leukemia (AML)", "Acute Biphenotypic Leukemia (ABL)", "Acute Undifferentiated Leukemia (AUL)" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5", "type": "DRUG" }, { "name": "Total Body Irradiation (TBI) 200cGy on Day -1", "type": "RADIATION" }, { "name": "Infusion of non-T-cell depleted bone marrow on Day 0", "type": "PROCEDURE" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Cyclophosphamide 50mg/kg/day IV on Days -2,-1", "type": "DRUG" }, { "name": "Cyclophosphamide 50mg/kg/day IV on Days -5,-4", "type": "DRUG" }, { "name": "Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1", "type": "RADIATION" }, { "name": "Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "Pre-HCT Mesna on Days -6 and -5", "type": "DRUG" }, { "name": "Pre-HCT Mesna on Days -2 and -1", "type": "DRUG" }, { "name": "Pre-HCT Mesna on Days -5 and -4", "type": "DRUG" }, { "name": "Post-HCT Mesna", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Center for International Blood and Marrow Transplant Research", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "15 Years to 70 Years" }, "enrollment_count": 80, "start_date": "2016-12", "completion_date": "2020-03", "has_results": true, "last_update_posted_date": "2025-08-06", "last_synced_at": "2026-09-18T07:45:17.277Z", "location_count": 11, "location_summary": "Gainesville, Florida • Miami, Florida • Tampa, Florida + 7 more", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02793544" } ] }